
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York - With the results of two previous open trials supporting clinical use of tacrolimus (Protopic) and pimecrolimus (Elidel), current data affirms that the topical immunomodulators are the definitive treatment of choice for facial and intertriginous psoriasis, according to Mark Lebwohl, M.D.